BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)GlobeNewsWire • 11/05/21
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 11/03/21
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/27/21
NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UKGlobeNewsWire • 09/16/21
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National StockpileGlobeNewsWire • 09/01/21
BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and SwissmedicGlobeNewsWire • 08/25/21
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Tuesday Afternoon Analyst Upgrades and Downgrades: Exxon Mobil, First Solar, Tesla and More24/7 Wall Street • 08/03/21